CA2603316A1 - Processus a etapes combinees pour compositions pharmaceutiques - Google Patents

Processus a etapes combinees pour compositions pharmaceutiques Download PDF

Info

Publication number
CA2603316A1
CA2603316A1 CA002603316A CA2603316A CA2603316A1 CA 2603316 A1 CA2603316 A1 CA 2603316A1 CA 002603316 A CA002603316 A CA 002603316A CA 2603316 A CA2603316 A CA 2603316A CA 2603316 A1 CA2603316 A1 CA 2603316A1
Authority
CA
Canada
Prior art keywords
levetiracetam
pharmaceutical
blend
process according
fluid bed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002603316A
Other languages
English (en)
Other versions
CA2603316C (fr
Inventor
Lina Al-Bargash
David A. Caron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mylan Pharmaceuticals ULC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA2603316A priority Critical patent/CA2603316C/fr
Priority claimed from PCT/CA2006/000470 external-priority patent/WO2006102750A1/fr
Publication of CA2603316A1 publication Critical patent/CA2603316A1/fr
Application granted granted Critical
Publication of CA2603316C publication Critical patent/CA2603316C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un processus pour la formulation pharmaceutique oral solide d~un ingrédient pharmaceutiquement actif tel que le lévétiracetam, comprenant une granulation par voie humide de l~ingrédient pharmaceutiquement actif et un séchage simultané à lit fluidisé, de sorte que lorsque le mélange pharmaceutique granule, il est simultanément séché, ce qui l'empêche de se transformer en pâte. Cette invention décrit donc un nouveau processus de préparation de formulation, caractérisé par une étape « combinée» comprenant un processus de granulation et un processus de séchage à lit fluidisé.
CA2603316A 2005-03-30 2006-03-30 Processus a etapes combinees pour compositions pharmaceutiques Expired - Fee Related CA2603316C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2603316A CA2603316C (fr) 2005-03-30 2006-03-30 Processus a etapes combinees pour compositions pharmaceutiques

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA2505463 2005-03-30
CA2,505,463 2005-03-30
PCT/CA2006/000470 WO2006102750A1 (fr) 2005-03-30 2006-03-30 Processus a etapes combinees pour compositions pharmaceutiques
CA2603316A CA2603316C (fr) 2005-03-30 2006-03-30 Processus a etapes combinees pour compositions pharmaceutiques

Publications (2)

Publication Number Publication Date
CA2603316A1 true CA2603316A1 (fr) 2006-10-05
CA2603316C CA2603316C (fr) 2014-11-18

Family

ID=38829386

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2603316A Expired - Fee Related CA2603316C (fr) 2005-03-30 2006-03-30 Processus a etapes combinees pour compositions pharmaceutiques

Country Status (1)

Country Link
CA (1) CA2603316C (fr)

Also Published As

Publication number Publication date
CA2603316C (fr) 2014-11-18

Similar Documents

Publication Publication Date Title
US8216611B2 (en) Combined-step process for pharmaceutical compositions
JP3563036B2 (ja) セレコキシブ組成物
US5266331A (en) Controlled release oxycodone compositions
US5656295A (en) Controlled release oxycodone compositions
JP6092936B2 (ja) 口腔内崩壊錠の製造方法
JP4868695B2 (ja) 崩壊性が良好な経口製剤
US20130011543A1 (en) Controlled release oxycodone compositions
MXPA04010496A (es) Tableta con alta carga de farmaco.
CN103402497A (zh) 快速分散颗粒、口腔崩解片以及方法
US20100034876A1 (en) Controlled release oxycodone compositions
JP2013534242A (ja) ナルブフィンを含有する製剤及びそれらの使用
CA2371231A1 (fr) Composition pharmaceutique sous forme unitaire contenant de l'acide acetylsalicylique et de l'hydrogenosulfate de clopidogrel
JP5048177B2 (ja) 放出制御製剤
US20070275065A1 (en) Controlled release oxycodone compositions
WO2006123213A1 (fr) Preparations a liberation modifiee de gliclazide
AU2011276450A1 (en) Pharmaceutical compositions containing vanoxerine
KR20150003726A (ko) 프라수그렐을 함유하는 안정한 즉시방출형 경구 약제학적 조성물
AU2012201676B2 (en) Combined-step process for pharmaceutical compositions
CA2603316C (fr) Processus a etapes combinees pour compositions pharmaceutiques
JP2002512964A (ja) レボシメンダンおよびアルギン酸からなる安定な組成物
CN105407875A (zh) 包含异烟肼颗粒和利福喷汀颗粒的呈包衣片剂形式的抗结核病的稳定的药物组合物及其制备方法
WO2005092319A1 (fr) Compositions pharmaceutiques a desintegration rapide, comprenant du nateglinide et un delitant
EA029709B1 (ru) Твердая пероральная лекарственная форма, содержащая декскетопрофен и трамадол, и способ ее изготовления
WO2014157603A1 (fr) Composition pharmaceutique pour administration orale
RU2289422C2 (ru) Фармацевтическая композиция на основе ноопепта

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220330